HPV-16 in Oral Cavity Associated With Increased Risk of Oropharyngeal Squamous Cell Carcinoma
Detection of human papillomavirus (HPV)-16 in the oral cavity may be associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.
Detection of human papillomavirus (HPV)-16 in the oral cavity may be associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.
Human papillomavirus 16 (HPV16)-positive patients with oropharyngeal squamous cell cancer (OPSCC) survive longer than HPV-negative patients.
In veterans, oropharyngeal squamous cell carcinoma (SCC) is associated with traditional carcinogens and poor clinical outcomes.
Human papillomavirus (HPV) type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma (OPC).
Several factors associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients.
The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).
The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.
Mixed views in relation to explaining causal role of human papillomavirus (HPV) in oropharyngeal cancer.
Oral malignancies can be associated with increased pain, but current research suggests that a cannabis-based spray may reduce this morbidity.
For patients with oropharynx cancer, HPV positivity is associated with improved survival after disease progression.